News | November 01, 2023
Ajanta Pharma posts Q2 FY24 consolidated PAT at Rs. 195.30 Cr
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
The inspection of the facility conducted from August 7 to August 11, 2023
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
With the establishment of five different precious metals alloy powder production methods
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Subscribe To Our Newsletter & Stay Updated
